Viewing nowEprosartan Tablets 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

MFDS item code 201905500 · Approved 2019.08.05 · Insurance code 622803710
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medicine is used to treat essential hypertension and is helpful in improving symptoms of heart failure (NYHA class II to IV) in patients intolerant to ACE inhibitors. It is also used to reduce the risk of mortality in stable patients with left ventricular dysfunction and reduced contractility after myocardial infarction. Therefore, it is effective in controlling essential hypertension, alleviating symptoms of heart failure, and reducing the risk of death after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this drug at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily, which may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, since there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication may cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimester, so it must be discontinued immediately upon confirmation of pregnancy. Pregnant women, women who may become pregnant, and breastfeeding women should not take this medication. It is not safe to use in patients with severely impaired liver function or specific liver diseases. Patients with hereditary angioedema or a history of angioedema should not take this medication. It is not administered to patients with severe renal impairment or specific kidney diseases. In diabetic patients with moderate to severe renal impairment, this medication should not be taken with certain concomitant medications. Caution is required when prescribing this medication to elderly patients or those with high serum potassium levels, and to patients with mild to moderate liver dysfunction. Patients with heart valve disease or cardiovascular diseases should be cautious when taking this medication due to the risk of complications resulting from blood pressure reduction. This medication may lower blood pressure sharply; therefore, patients at risk of hypotension should start at a low dosage and be closely monitored. Special care is needed when administering to patients undergoing dialysis, those with strict salt restrictions, and patients shortly before surgery. Caution is also advised when taken with other antihypertensives, certain diuretics, and potassium-sparing medications, as drug interactions may increase the risk of side effects. This medication contains the dye Yellow No. 5, so patients allergic to this substance should use it cautiously. Side effects such as headache, dizziness, fatigue, cough, dyspepsia may occur during treatment. If any abnormal symptoms persist or worsen, consult a doctor immediately. Patients with heart failure or post-myocardial infarction may experience changes in renal function, so regular kidney function testing is necessary. This medication may raise serum potassium levels; therefore, patients with hyperkalemia or those at risk of hyperkalemia should monitor serum potassium levels periodically. The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age, so it is advisable not to use it in this age group. Overdose can lead to hypotension, decreased consciousness, etc., so the dosage must be strictly followed, and if an overdose occurs, contact a medical institution immediately. Store this medication out of reach of children and do not transfer it to another container for safety. Caution is required as dizziness may occur while driving or operating machinery.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly closed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.
Oval film-coated tablet in orange color with a grayish tint
30 tablets/bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.